Despite decades of research, there are still only limited treatments and no cures available for most brain diseases. Through NCADD’s unique unbiased scientific approach, combining deep patients’ characterization and artificial intelligence, we aim to address major challenges in the neuroscience field: finding biomarkers for neurological disorders, enabling drug target discovery, and facilitating the development of personalized therapies.



By collaborating with multiple Quebec-based biotech companies and national and international collaborators, we dedicate our efforts to deeply characterizing patients affected by Parkinson’s disease, schizophrenia, or bipolar disorder, both clinically and at the cellular level via multiple biological assays. We also develop artificial intelligence-based approaches to classify patients into distinct subgroups and discover new disease biomarkers, using this deep characterization data.



Financed by the Ministry of Economy, Innovation and Energy’s “Fonds D’Accélération des Collaboration en Santé” (FACS) program, NCADD’s core objective is to be a catalyst for public-private collaborations and for growth of the life science sector in Quebec. With this in mind, we work closely with multiple talented biotech partners, which are in majority Quebec-based.


What's new?

The Neuro-CERVO Alliance Partners with Montreal-based AI Company Simmunome to Understand Neurological Disease Mechanisms and Accelerate Drug Development

MONTREAL, Canada, July 18, 2023 In the newly established initiative, the Neuro-CERVO Alliance for Drug Discovery (NCADD) is welcoming a…

Read the article

New Quebec neuroscience partnership awarded $7M

The Neuro and the CERVO Brain Research Centre join forces to pave the way for much needed biomarker discovery in…

Read the article

Open Science to speed up the drug discovery process

How can sharing data openly accelerate PD research? https://www.mcgill.ca/neuro/article/open-science-stories-research-stories/accelerating-drug-discovery-open-science

Read the article